Opendata, web and dolomites

InTheMLLrBALL SIGNED

Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InTheMLLrBALL project word cloud

Explore the words cloud of the InTheMLLrBALL project. It provides you a very rough idea of what is the project "InTheMLLrBALL" about.

pd1    immunotherapy    mainly    trials    d1    cell    mllr    fundamental    rearrangements    immune    express    refractory    adoptive    tandem    mechanism    transfer    single    position    microenvironment    alls    chemotherapy    reduce    vitro    plan    training    chimeric    receptors    benefited    offset    leukemia    pd    combination    escape    lymphoblastic    clinical    blasts    shown    lineage    interplay    domains    with    engineered    ag    containing    bispecific    independent    impressive    patients    responded    modify    pd1l    occurs    molecule    disease    surface    mesenchymal    scientific    complementary    edge    mixed    cancer    cars    mllrb    leadership    pressure    car    strategy    prognosis    near    therapy    mediated    host    commonest    cutting    stroma    contribution    cells    artificial    relapse    remission    blockade    l1    tumor    stromal    efficiency    vivo    antigen    acute    persistence    cd19    indirect    clinically    children    dismal    binding    ng2    efficacy   

Project "InTheMLLrBALL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS 

Organization address
address: CARRER MUNTANER 383 3/2
city: BARCELONA
postcode: 8021
website: www.carrerasresearch.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

B-cell acute lymphoblastic leukemia (B-ALL) is the commonest cancer in children and B-ALL with mixed-lineage leukemia rearrangements (MLLr) has a particularly dismal prognosis compared with other B-ALLs. Many MLLrB-ALL patients are refractory to chemotherapy and eventually relapse. Thus, MLLrB-ALL remains clinically challenging. Adoptive transfer of T cells engineered to express artificial chimeric antigen (Ag) receptors (CARs) targeting tumor cell surface-specific Ag is an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B-ALL treated with CAR-T cells against CD19 have shown impressive disease remission; however relapse still occurs with loss of CD19. Importantly, the B-ALL patients who have not responded to CD19 CAR-T cells were mainly those carrying MLLr. A strategy to offset tumor Ag-loss relapse is to modify T cells with one CAR molecule containing two different binding domains in tandem (bispecific CAR). By using both in vitro and in vivo approaches, I plan to improve CD19 CAR-T cell therapy for MLLrB-ALL by i)developing a novel bispecific CD19/NG2 CAR, which we expect will reduce single-Ag immune pressure, and ii)through the combination of CD19 CAR-T cell therapy with P-D1/PD-L1 blockade. How to achieve a long-term persistence of CAR-T cells in the host still remains a major challenge in adoptive T cell immunotherapy, and therefore understanding the interplay between T cells, MLLrB-ALL blasts and mesenchymal stromal cells/stroma is fundamental to improve the efficiency of this immunotherapy. We will thus address in vitro and in vivo the contribution of the leukemia microenvironment to CAR-T cell efficacy, as a potential tumor microenvironment (PD1/PD1L)-mediated indirect mechanism of immune escape to CAR T-cells. This cutting-edge proposal will increase my scientific potential and I will be benefited with the complementary/leadership training activities already planned to reach in a near future an independent position.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTHEMLLRBALL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTHEMLLRBALL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PHOTOCARBOX (2020)

Increasing the scope of CO2-utilising photoreactions: asymmetric photosynthesis of amino acids

Read More  

EngPTC2 (2019)

Exploring new technologies for the next generation pulse tube cryocooler below 2K

Read More  

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More